stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Current ratio
Veracyte, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 5.6×, down 2.6× from fiscal 2025 (8.1×). Over the past ten years it has ranged from 3.3× (fiscal 2015) to 22.4× (fiscal 2020); the current reading is higher than 82% of that period. That is above the Diagnostics & Research industry median of 2.3× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 8.1× | 72.11% |
| FY2024 | 4.7× | 1.51% |
| FY2023 | 4.7× | 17.45% |
| FY2022 | 4.0× | 4.79% |
| FY2021 | 3.8× | (83.07%) |
| FY2020 | 22.4× | 108.37% |
| FY2019 | 10.7× | 44.72% |
| FY2018 | 7.4× | 65.59% |
| FY2017 | 4.5× | (29.76%) |
| FY2016 | 6.4× | 96.14% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 5.6× | (39.35%) |
| Jun 2026 | 9.2× | (1.54%) |
| Mar 2026 | 9.3× | 14.20% |
| Dec 2025 | 8.1× | 30.87% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| BLLN BillionToOne, Inc. compare | 11.2× |
| GRAL GRAIL, Inc. compare | 8.9× |
| VCYT Veracyte, Inc. | 5.6× |
| ADPT Adaptive Biotechnologies Corporation compare | 4.0× |
| NEO NeoGenomics, Inc. compare | 3.5× |
| WGS GeneDx Holdings Corp. compare | 3.3× |
| SHC Sotera Health Company compare | 3.1× |
| CDNA CareDx, Inc. compare | 2.3× |
| RDNT RadNet, Inc. compare | 1.5× |
| Diagnostics & Research industry median | 2.3× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement